Total Raised

$610K

Funding, Valuation & Revenue

6 Fundings

Full Genomes has raised $610K over 6 rounds.

Full Genomes's latest funding round was a Unattributed - VI for $0.02M on May 9, 2016.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

5/9/2016

Unattributed - VI

$0.02M

Undisclosed Investors

$XXM

0

FY undefined

1

10/26/2015

Unattributed - V

$XXM

$XXM

0

FY undefined

10

9/14/2015

Unattributed - IV

$XXM

$XXM

0

FY undefined

10

12/9/2014

Unattributed - III

$XXM

$XXM

0

FY undefined

10

12/9/2014

Unattributed - II

$XXM

$XXM

0

FY undefined

10

Date

5/9/2016

10/26/2015

9/14/2015

12/9/2014

12/9/2014

Round

Unattributed - VI

Unattributed - V

Unattributed - IV

Unattributed - III

Unattributed - II

Amount

$0.02M

$XXM

$XXM

$XXM

$XXM

Investors

Undisclosed Investors

Valuation

$XXM

$XXM

$XXM

$XXM

$XXM

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

1

10

10

10

10

Start free trial
New call-to-action
New call-to-action

Compare Full Genomes to Competitors

Helix Logo
Helix

Helix focuses on integrating genomics into healthcare, medical research, diagnosis, treatment, and prevention within the health systems, public health, and life sciences sectors. The company provides access to genomic data for health systems, life sciences companies, and public health organizations. It was founded in 2015 and is based in San Mateo, California.

Somos Logo
Somos

Somos focuses on ancestry services and genetic analysis within the biotechnology sector. The company offers deoxyribonucleic acid (DNA) testing kits and a platform for Latino ancestry analysis, highlighting personal data ownership and collaboration with Indigenous nations. Somos aims to improve health solutions and drug discovery for Latin American populations by utilizing genomics and data analysis. It was founded in 2020 and is based in San Francisco, California.

Laureate Pharma Logo
Laureate Pharma

Laureate Pharma is a company focused on biopharmaceutical services within the healthcare sector. The company specializes in the synthesis of pharmaceutical substances, production of interleukins, and the creation of finished dosage forms, with a strategic emphasis on developing and launching pulmonary drugs. Laureate Pharma maintains a full production cycle from substance synthesis to final drug production. It is based in Princeton, New Jersey.

Blaze Systems Logo
Blaze Systems

Blaze Systems focuses on Laboratory Information Management Systems (LIMS) within biotechnology, clinical labs, discrete manufacturing, electronics, environmental laboratories, food and beverage, pharmaceutical, and process industries. The company provides LIMS products and services that automate lab processes, manage sample data, and ensure regulatory compliance. Blaze Systems serves sectors that require lab management and regulatory adherence, including pharmaceuticals, environmental testing, and food safety laboratories. It was founded in 1991 and is based in Newark, Delaware.

P
Punjab Biotechnology Incubator

Punjab Biotechnology Incubator is a biotechnology research and development organization that operates in the agri-food biotechnology sector. The company provides analytical testing, consultancy, advisory support, skill development, training programs, and incubation services for startups. Punjab Biotechnology Incubator serves sectors including food and agriculture, water management, environmental protection, agricultural inputs, animal food and feeds, and the pharmaceutical and AYUSH industry. It is based in India.

J
J. Lamarck

J. Lamarck is a company that offers advisory services to private individuals, companies and pension funds who want to invest in the biotechnology sector.nThe company offers a high quality service and its analyst provide professional assistance to people who want to diversify a part of their portfolio in this emerging industry. Because of the nature of biotechnology investments, the company believe it is important that users work with specialists to define their portfolio strategy. Generally, specialists do things better.nOver the next few years the company will be witness of astonishing progress in health care and medicine, the company will be able to fight and cure diseases like AIDS and cancer finally. The company will also find solutions to clean up the environment and new crops that don't need pesticide. These new products will obviously boost the visibility of the companies that were at the beginning of this process on the stock market and consequently create great opportunity for it's shareholders.nJ. Lamarck wants to be their partner in this great venture.

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.